Overcoming the reimbursement barriers for clinical sequencing

JAMA - Journal of the American Medical Association

Volumn 312, Issue 18, 2014, Pages 1857-1858

  Deverka, Patricia A ^a   Kaufman, David ^b   McGuire, Amy L ^c  

^a University of North Carolina at Chapel Hill   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST CONTROL; EXOME; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; GENETIC PROCEDURES; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MEDICAL DECISION MAKING; NEXT GENERATION SEQUENCING; PHENOTYPE; PRACTICE GUIDELINE; REIMBURSEMENT; RELIABILITY; SHORT SURVEY; VALIDITY; DECISION MAKING; ECONOMICS; EVIDENCE BASED PRACTICE; GENETIC SCREENING; HIGH THROUGHPUT SEQUENCING; INSURANCE; REPRODUCIBILITY; STANDARDS;

DECISION MAKING; EVIDENCE-BASED PRACTICE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH, REIMBURSEMENT; REPRODUCIBILITY OF RESULTS;

EID: 84918791973     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.14915     Document Type: Short Survey

References (7)

1. Walsh JM, Goldberg JD. Fetal aneuploidy detection by maternal plasma DNA sequencing: a technology assessment. Prenat Diagn. 2013;33 (6):514-520.
2. BlueCross BlueShield of North Carolina. Corporate Medical Policy: Whole Exome Sequencing. http://www.bcbsnc.com/assets /services/public/pdfs/medicalpolicy/whole-exome -sequencing.pdf. October 2013. Accessed October 15, 2014.
3. Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA. 2014;311(10):1035-1045.
4. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Commitee. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-747.
5. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med. 2013; 369(25):2369-2371.
6. Veenstra DL, Piper M, Haddow JE, et al. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med. 2013;15(1):14-24.
7. Elenitoba-Johnson KSJ, Kiel MJ. Consensus standards for multiplex cancer genomic testing: Joint roundtable fosters awareness of expectations. ASCO Daily News. June 1, 2014. http://www.am.asco .org/consensus-standards-multiplex-cancer -genomic-testing-joint-roundtable-fosters -awareness-expectations. Accessed October 15, 2014.